BioMarin schedules third-quarter results. BioMarin stock is valued at USD 10.7 billion
Published on 10/28/2026 at 06:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBioMarin's upcoming results
- BioMarin presented data from 13 studies on October 9, 2026.
- Second-quarter revenue reached USD 989.7 million, up 19.9 percent year over year.
- BioMarin had a USD 10.7 billion market value as of October 27, 2026.
BioMarin Pharmaceutical Inc. (ISIN US09061G1013) will discuss its third-quarter 2026 results on November 2, 2026, at 4:30 p.m. ET. The company said on October 26, 2026, that Chief Executive Officer Alexander Hardy will host the webcast and provide a business update, according to BioMarin Pharmaceutical.
Revenue sets the starting point
BioMarin's second-quarter revenue reached USD 989.7 million, up 19.9 percent year over year, while net product revenue totaled USD 984.4 million versus USD 813.0 million in the prior-year quarter, according to AlphaStreet. The company also reported adjusted diluted earnings per share of USD 1.20 against a USD 0.95 consensus estimate, a 26.6 percent difference.
The earnings call will provide the next operating test after BioMarin completed its Amicus acquisition in April 2026. The first half of 2026 produced USD 1.756 billion in revenue, compared with USD 1.571 billion in the first half of 2025, an 11.8 percent increase. Adjusted operating margin was 36.4 percent in the second quarter, down 3.6 percentage points year over year.
What will November 2 test?
Baird reiterated a Neutral rating and a USD 65.00 price target on October 27, 2026, while cutting its non-GAAP third-quarter earnings-per-share estimate from USD 1.40 to minus USD 0.01. The firm cited acquired research and development costs linked to Alesta and revised operating-expense expectations, as reported by Investing.com. That estimate makes the November 2 update important for judging the balance between Amicus integration costs and revenue growth.
Three dated steps in the story
On August 6, 2026, BioMarin reported second-quarter revenue of USD 989.7 million. On October 9, 2026, it announced data from 13 studies at the American Society for Bone and Mineral Research meeting, according to BioMarin Pharmaceutical. On October 26, 2026, it scheduled the third-quarter results call for November 2, 2026.
Next date for investors
The next substantiated company date is November 2, 2026, the third-quarter results call at 4:30 p.m. ET.
Market value before results
BioMarin had a USD 10.7 billion market capitalization as of October 27, 2026. Its 52-week range was USD 49.26 to USD 70.98 on the same date.
The further course of trading is shown by the continuously updated real-time quote of BioMarin stock.
BioMarin stock facts
- Company: BioMarin Pharmaceutical Inc.
- ISIN: US09061G1013
- Ticker: BMRN
- Primary exchange: Nasdaq
- Market capitalization: USD 10.7 billion (as of October 27, 2026)
- 52-week range: USD 49.26-70.98 (as of October 27, 2026)
- Sector / Industry: Health care / Biotechnology
Market context: Market report S&P 500.
